Your One Stop Shop for Healthier Living

With over a quarter of a century of Research and Development focusing on Early Detection, RMDM helped launch the pioneering cancer blood test and imaging screening program that can detect all cancers at any stage: PanTum Detect.

PanTum Detect® represents a significant advancement as pan-tumor blood test for screening of asymptomatic healthy population.

PanTum Detect + Imaging Screening: A True Game Changer in Cancer Diagnostics

A screening program, incorporating the PanTum Detect test and imaging, enables the detection of asymptomatic individuals needing further evaluation who might have otherwise remained undetected.

With just one blood sample, it is possible to confirm cancer suspicion and detect potential tumours in their earliest stages of development.

Non Invasive: a simple blood test/draw, done in a lab or clinic
Accurate: 99.53% specific and 95.21% sensitive (unmatched in cancer diagnostics)
Universal: can detect the presence of any kind of tumour via the novel use of 2 unique biomarkers
Affordable: the simple technology allows you to do a yearly screening check
Possibility of localization and classification of detected tumours
Exposure to radiation only when necessary

Pantum detect blood test for the early detection of cancers

Middle aged woman sitting in a chair getting a blood test done by a female nurse

Can a blood test detect cancer?

PanTum Detect is a CE-certified IVD blood test that can detect the presence of any suspicious tumour at any stage of development, which is based on the detection of epitopes in monocytes.

Activated monocytes (macrophages) phagocytose unwanted cells/cell fragments from the whole body including tumour cells from solid tissues. As they return to the blood macrophages can be used for non-invasive detection of the biomarkers (Apo10 & TKTL1), thereby providing high sensitivity and specificity, because the intracellular presence of biomarkers is not diluted.

Flow cytometry analysis of blood enables the detection of macrophages and phagocytosed intracellular biomarkers. In order to establish a pan-cancer test, biomarkers for two fundamental biophysical mechanisms have been exploited.

The DNaseX/Apo10 protein epitope is a characteristic of tumour cells with abnormal apoptosis and proliferation. Transketolase-like 1 (TKTL1) is a marker for an anaerobic glucose metabolism (Warburg effect), which is concomitant with invasive growth/metastasis.
The test has already proven its capabilities with over 160,000 blood samples analysed across 50 tumour entities.

Pantum Detect will not only help prevent cancer related deaths via a regular screening check for healthy people but will also massively reduce the cost and strain on the healthcare system. It is truly a breakthrough in cancer care!

E.D.I.M Epitope Detection In Macrophages

The EDIM technology makes use of the body’s immune system; these steps explain how the technology works:

Macrophages migrate from blood into tissue.
Macrophages phagocytose degenerated tumour cells.
Macrophages with absorbed tumour-specific structures migrate back into the blood.
PanTum Detect - The phagocytosed tumour cells are examined.

1. Macrophages migrate from blood into tissue.

2. Macrophages phagocytose degenerated tumour cells.

3. Macrophages with absorbed tumour-specific structures migrate back into the blood.

4. Pantum Detect – The phagocytosed tumour cells are examined.

PanTum Detect + Imaging: The Ideal Combination

Potentially dangerous tumours are able to be detected at a very early stage using imaging methods (such as MRI, PET/CT, etc.); but these methods cannot be used for a national screening program due to the high costs, lack of access, and potentially harmful radiation.

Combining PanTum Detect with modern imaging allows for safe cancer screening by filtering out non-cancer suspicious patients.

In 2022, a large-scale study (study publication) with over 5,000 asymptomatic subjects, PanTum Detect successfully identified cancer-suspicious patients justifying a follow-up examination ( using imaging methods).

The study confirms that PanTum Detect annual screening can provide early detection of tumours, leading to increased survival rates.
With a PPV (positive predictive values) = 98.95% there is a very low rate of false positives, making it ideal for a nationwide screening program.

Private lecturer Dr G.-Andre Banat, MBA, summarises the applicability of the new findings as follows:

“The study results suggest that this combination of the PanTum Detect blood test and imaging methods can close significant gaps in effective early cancer detection.”

High Sensitivity & Specificity

Through EDIM technology we have achieved high sensitivity and specificity results.

Sensitivity

PanTum Detect identifies 95.21% of 100 tumour patients.
PanTum Detect reaches this high sensitivity because tumour-specific structures are well-conserved and highly concentrated inside the macrophages.

Specificity

Specificity is the most important KPI (Key Performance Index) for screening tests.
PanTum Detect reaches this high specificity by leveraging the extremely specific immune system (detection of biomarkers in macrophages).

Over 50 cancer types were detected in studies using the PanTum Detect tumour markers:

Adenocarcinoma, Aerodigestive Cancer, Astrocytoma, Pancreatic Cancer, Bladder Cancer, Bronchial Cancer, Breast Cancer, Cholangiocarcinoma (Biliary CA), Colorectal Cancer, DIPG / "Pons Gliomas", Triple Negative Breast Cancer, Ductal Carcinoma, Ovarian Cancer, Endometrial Cancer, Ependymoma, Gastroesophageal Transition Cancer, Cervical cancer, Uterine cancer, Brain tumour, Glioblastoma, Granulosa cell tumour, Gynaecologic cancers, Hepatoblastoma, HER2 positive breast cancer, Hyperplasia, Small cell lung cancer, Head and neck cancer, Lung cancer, Lymphoma tumours, Gastric cancer, Malignant conjunctival tumours, Medulloblastoma, Melanoma tumours, Nasopharyngeal carcinoma, Neoplastic lung tissue, Nephroblastoma, Non-metastatic rectal adenocarcinoma, Non-small cell lung cancer, Renal cancer, Oral squamous cell carcinoma OSCC, Estrogen receptor (ER)-positive breast cancer, Squamous intraepithelial neoplasm (SIN I - III), Squamous cell carcinoma, Squamous cell carcinoma of breast, Squamous cell carcinoma of the prostate, Squamous cell carcinoma of the esophagus (ESCC), Progesterone receptor (PR)-positive breast cancer, Prostate cancer, PSA-positive prostate cancer, PSMA-positive prostate cancer, Rectal cancer, Rhabdomyosarcoma, Thyroid cancer (follicular and papillary), Tumours of the eye appendage, Urothelial cancer, Vaginal cancer, Vulvar cancer

Note: Previously tested lymphomas and leukemias have also shown to be positive for PanTum Detect, but are not included in this list of solid tumours.

Disclaimer: This list contains information from publications and information from clinical practice in real testing situations.





Can you define these biomarkers and is the test cancer specific?

PanTum Detect is a pan-tumour test, able to detect the presence of any suspicious tumour. Combined with the imaging methods such as MRI, PET/CT, the screening program offers a high probability of localization and classification of detected tumours.

The biomarkers that are exploited and unique to PanTum are for two fundamental biophysical mechanisms. The DNaseX (Apo10) protein epitope is a characteristic of tumour cells with abnormal apoptosis and proliferation. Transketolase-like 1 (TKTL1) is a marker for anaerobic glucose metabolism (Warburg effect), which is concomitant with invasive growth/metastasis and resistant to radical and apoptosis-inducing therapies.





What is the technology used for analysis?

Flow cytometry analysis of blood enables the detection of macrophages and phagocytosed intracellular biomarkers. There is an integrated gating and algorithmic analysis within the flow cytometer.





What happens if a customer receives a tumour-suspicious result?

If a customer receives a tumour-suspicious result, a prompt and efficient physician consultation will be organized and the follow-up examination (such as PET/CT or MRI) and a referral to an oncologist in case the initial suspicion is confirmed.





What are the specificity and sensitivity results of PanTum Detect?

PanTum Detect is extremely accurate, identifying cancer with 99.53% specificity and 95.21% sensitivity, minimizing the risk of false positives and false negatives.



